Check out our recent work on GBM’s heterogeneity. Non-enhancing tumor margins as well as enhancing cores were queried for therapeutic vulnerability with interesting results. @NeuroOnc@DoctorQMd@Wan_HsinLin@pzanastasiadis@EMiddlebrooksMD
https://t.co/ziUcdQqP3D
Great discussion on the INDIGO trial! Great opportunity to learn from some of the giants in the field #SusanChang @MartinvdenBent #PatrickWen. A lot of work to do, but the future is bright. #glioma#BrainCancer
🎉 Happening today! Earn free CME!! SNO Grand Rounds Series: IDH-Mutant Glioma: Pivotal Results and Discussion of the INDIGO Trial. September 12, 2023, from 12:00-1:00 pm ET. Register now: https://t.co/slwz2UpPY3